A REVIEW ARTICLE ON TRANSEDERMAL PATCHES USED FOR MUSCLE RELAXATION

A REVIEW ARTICLE ON TRANSEDERMAL PATCHES USED FOR MUSCLE RELAXATION

Nisha Ballarpure, Neha Yadav and Anmol Dhawande *

School of Pharmacy, G. H. Raisoni University, Saikheda, Pandhurna, Madhya Pradesh, India.

ABSTRACT: Transdermal drug delivery system (TDDS) is an emerging modality in drug administration of skeletal muscle relaxants (SMRs), which have significant benefits in comparison to traditional oral and injectable delivery methods. Including tizanidine and baclofen, which often exhibit poor bioavailability, first-pass liver metabolism, and overall systemic adverse effects, including sedation and gastrointestinal malfunctions. These restrictions are especially harmful to the elderly population and chronically comorbid patients. TDDS bypass such limitations, and as a result, they can be used to effect transcutaneous drug delivery. It examines a range of transdermal patch technologies, such as matrix and reservoir systems, and novel carriers, such as aspasomes and niosomes that have been designed to overcome the cutaneous barrier. Besides, the paper outlines formulation plans that include penetration enhancers and polymer matrix, and any preclinical and limited clinical data that supports the effectiveness and patient compliance of such systems. As the substantive issues remain largely similar, namely, the limitations of skin permeability and the necessity of large-scale clinical trials, the emergence of transdermal SMRs gives a more patient-friendly method, safer, and more effective option in the treatment of musculoskeletal diseases.

Keywords: Transdermal drug delivery systems (TDDS), Skeletal muscle relaxants (SMRs), Tizanidine, Bioavailability, First-pass metabolism, Patient adherence, Formulation strategies, Clinical trials

INTRODUCTION: Recent developments on TDDS have focused on enhancing the drug permeation, improving patient compliance and increasing the therapeutic repertoire which could be administered through the skin. New techniques include microarray of micro needles, iontophoresis, ultrasound-delivery, and nanoparticles, Moreover, wearable transdermal patches that combine stimulus-responsive drug delivery materials and electronic functions have been evaluated as a means to provide on-command and controlled release of drugs to provide personalized treatments.

The integration of intelligent technologies in TDDS aims to achieve the precise modulation in time and space of drug release, which enhances therapeutic and suppresses adverse effects. It is expected that these advancements will expand the clinical use of TDDS both to treat chronic illnesses, manage pain, and replace hormones and, in the same breath, overcome issues related to skin penetration and patient compliance.

An Overview of Skeletal Muscle Relaxants (SMRs): Skeletal muscle relaxants (SMRs) are a group of pharmacological agents, which are often utilized to reduce muscular hyper tonicity, spasmodic and nociceptive manifestations of various musculoskeletal pathologies. These conditions include, but are not limited to, multiple sclerosis, spinal cord injury, cerebral palsy and acute musculoskeletal trauma. The main pharmacodynamics effect of SMRs is the decrease in muscle tone through central nervous system modulation or peripheral muscular interaction, hence reduce involuntary myoclonic contractions, therapeutically benefit the patient, and improve mobility, which can be obtained during therapeutic treatment ¹.

They are regularly prescribed in relation to acute myofascial activities and in relation to chronic diseases like myofascial pain syndrome and hypertonic pelvic floor disorders. However, the SMRs have much more than just muscle relaxation effects ².

Oral and parenteral SMRs have a number of limitations despite their efficacy. Oral route is affected by the first-pass hepatic metabolism, which leads to a variation in the kinetic absorption and requires an enhanced or more frequent dosing. Sedation, cognitive dysfunction, and gastrointestinal issues are adverse events that make therapy more challenging especially in geriatric patients who poly-medicate and with comorbidities. These problems shed some light on the need of new modalities of delivery that would not compromise therapeutic efficacy and minimize negative outcomes. The pharmacokinetic patterns and safety histories of medications like tizanidine and baclofen have catalyzed new investigative interest towards new preparations particularly among the elderly who form a significant demographic group requiring SMRs ³.

FIG. 1: MECHANISM OF TRANSDERMAL PATCHES

The Importance of Transdermal Drug Delivery Systems (TDDS): Transdermal drug delivery system (TDDS) has emerged as a modality that is becoming increasingly popular and patient-focused in the delivery of therapeutic agents. In contrast to the oral or injected methods. It is especially beneficial to SMRs, as they tend to have poor oral bioavailability or produce side effects that are not desired ⁴. There are various advantages of TDDS. They also allow regulated and prolonged pharmacokinetic delivery to maintain constant plasma drug concentrations and eliminate the peak-trough effect of traditional dosage forms, which is usually associated with side effects and reduced efficacy, like a pediatric or geriatric patient ⁵. When it is crucial not to expose a whole organism to the drug, but rather to deliver it to particular musculature, TDS may be used, which may improve treatment response and decrease systemic toxicity. The skin is highly vascularized and easily accessible thus making it a valid route of drug administration both systemically and locally. In the case of SMRs, Additionally, the applicable nature of TDDS makes it possible to explore other methods of delivery, thus expanding the number of therapeutic options that focus on the patient ⁶.

FIG. 2: DRUG DELIVERY PROCESS THROUGH TRANSDERMAL PATCH

Purpose and Scope of the Review: As a new patient-centered form of drug delivery, transdermal drug delivery systems (TDDS) have continued to gain momentum in use as a treatment delivery method. In contrast to traditional oral or parenteral methods. TDDS is associated with a wide range of benefits, such as controlled and sustained delivery of drugs that produce constant plasma levels, thus reducing the tendency of most traditional dosage forms to cause peak-to-trough fluctuations. Such inconsistency is often associated with unpleasant incidents and low treatment efficiency. In addition, transdermal patches also facilitate patient compliance due to painless and non-invasive delivery and simplified dosing schedules, a factor of utmost importance to patients with dysphagia or who do not respond positively to injections, e.g. children and the elderly.

This effect increases the effectiveness of the therapy, as well as minimizes the rate of side effects on the system. Skin has a high degree of vascularization and is easily accessible, which makes it a very effective route of systemic and local drug delivery. The PDDS versatility also makes it easier to explore alternative delivery systems, including buccal patches, nasal sprays, and in situ gels and increase patient-centred treatment choices.

Pharmacological Characteristics of Muscle Relaxants Appropriate for Transdermal Administration:

Commonly Used Muscle Relaxants and How They Work: Suitable muscle relaxants that can be administered as transdermal have their effect largely in the central nervous system, it alters neural circuits of muscle tone control. The representative agents are tizanidine, baclofen, and tolperisone, which have different mechanisms of action and clinical manifestations that are different ¹. On the same note, baclofen is an agonist of GABA_B receptors, which relaxes the muscles by stimulating inhibitory neurotransmission, hence decreasing spasticity. Tolperisone is a derivative of the piperidine group that acts on the reflex activity of the spine and operates through an unclear mechanism. It is said to have fewer side effects of sedation compared to other skeletal muscle relaxants ². It is also not associated with big risks of physical dependence or the possibility of abuse as opposed to other drugs like carisoprodol and diazepam. Such pharmacological differences make tizanidine especially appropriate in an elderly population, which can be confirmed by the fact that the drug has not been listed in the American Geriatrics Society Beers Criteria of potentially inappropriate medication use. The pharmacodynamics and safety differences between them would require a prudent choice of a suitable muscle relaxant to be used in transdermal ⁸.

Tizanidine: An Examination: Tizanidine is an example of a generic muscle relaxant to be used in transdermal delivery due to its favorable pharmacological and pharmacokinetic properties. Being a selective α – adrenergic receptor agonist, it is useful in relieving spasticity and pain. Limiting its use when administered through the traditional routes ¹. In addition to spasticity, neuropathic analgesia, gastro protection with non-steroidal anti-inflammatory agents, and combination with other modalities of pain management, including early postoperative analgesia. There is further emerging evidence of possible antineoplastic effects and as such, expands therapeutic opportunities ².

Tizanidine is also in research of alternative delivery methods which are in development such as buccal patches, nasal sprays and mostly transdermal preparations in an attempt to overcome the limitations of oral dosage. These new formulations are developed to enhance the drug bioavailability, reduce systemic adverse effects leading to better clinical outcomes ⁷.

FIG. 3: TIZANIDINE FORMULATIONS ON THE MARKET UNDER DEVELOPMENT

Problems with Transdermal Delivery of Muscle Relaxants: Although there are good benefits of transdermal delivery, there are still numerous challenges in the implementation of muscle relaxants through this modality. The first barrier is that the skin, especially, stratum corneum, has a complicated structure that provides severe physico-chemical limitations on the size, lipophilicity, and polarity of molecules permeation through the skin ⁵. Additionally, systemic metabolism inter-individual variation through cutaneous enzyme-mediated metabolic transformation, e.g. cytochrome P450 polymorphisms as typified by CYP2C19, and drug bioavailability are also mediated by metabolic transformation. These considerations require careful attention to patient-related variables ⁹.

Genetic heterogeneity also creates a further complication to the efficacy and safety profile of the transdermal muscle relaxant therapy. Differences in metabolic enzymes and receptor genes are capable of modulating the response in patients and therefore the need to have individual approaches in designing and implementing transdermal selective muscle relaxants. Formulation characteristics and patient factors should be carefully assessed to achieve maximum therapy and safety ¹⁰.

Formulations and Technologies for Transdermal Patches for Muscle Relaxants:

Different Kinds of Transdermal Patches and Ways to Deliver Them: Transdermal patches constitute an eclectic pool of technologies of delivering, which is used to administer pharmacological agents transskinally. Other modalities, including buccal patches, nasal sprays and in situ rectal gels have been designed to avoid oral absorption and to avoid first-pass hepatic metabolism, thus increasing patient convenience and allowing localized and systemic access of drugs ⁷. Aspasomes, a new type of amphiphilic vesicles, have shown promise in enhancing transdermal absorption and increasing the bioavailability of tizanidine, as a nanoplatform to deliver therapeutic muscle-relaxant nanoparticles ¹¹. Another versatile carrier of skeletal muscle relaxant agents and other pharmaceuticals is niosomes. Hydrogels add a biocompatible scaffold that affords water solubility and allows diffusion of drugs thus broadening the range of existing transdermal delivery systems ¹².

FIG. 4: DIFFERENT TYPES OF TRANSDERMAL DRUG DELIVERY PATCHES

Strategies for Making Sustained and Controlled Release: The transdermal patches that are state-of-the-art use ethyl cellulose, hydroxypropyl methylcellulose (HPMC), Eudragit RL 100 and polyvinylpyrrolidone (PVP) to control the release of drugs precisely. Flexibility is improved by the use of plasticizers, such as N -dibutyl phthalate, and also patch bonding. Systems based on dichloromethane, ethanol and chloroform are used as solvents that provide a uniform dispersion of drugs during the manufacturing process. Drug loss does not occur as membranes composed of polyethylene film support or membranes composed of aluminum foil are used to shield the patch ¹². Essential analytical methods such as Fourier-transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) are used to explain the relationship between the drug and polymer matrix and the crystalline form of the drug in the patch ¹³.

The Kinetic modeling, such as the Korsmeyer Peppas model, is used to explain the logic behind drug release. Optimized formulation often have an anomalous release where diffusion and polymer relaxation work in concert to cause the desired release profile. These strategies of formulation are essential in stabilizing the drug, its release rate, and comfort in patients ¹⁴.

Things That Make Skin Permeation Better and Ways to Do It: Iontophoresis is non-invasive method of drug delivery enhancement. As an example, alternating-current iontophoresis has also been explored in the delivery of local anesthetic into the skin, with positive results in terms of controlling postoperative pain ¹⁵.

The synergistic combination of chemical enhancers with physical modalities can be used to provide combination strategies to raise permeation levels, leading to therapeutic transdermal drug concentrations, which would have otherwise not been possible. In order to translate transdermal systems into standard clinical practice, continuing studies on these combined approaches are necessarily ¹⁶.

Clinical and Preclinical Evidence of Transdermal Muscle Relaxant Effectiveness:

Studies before Clinical Trials and Pharmacokinetic Tests: Preclinical studies highlight the better bioavailability and absorption rates of muscle relaxants when applied through the skin. Pharmacokinetic tests in Wistar rats confirmed that these formulations had significantly better bioavailability and longer-lasting plasma concentrations compared to oral tizanidine. Ex vivo permeation studies using synthetic membranes and excised animal skin further support the improved delivery potential of transdermal formulations. Evaluations of skin irritation consistently reported minimal adverse reactions, which helps with safety concerns for clinical use ⁷.

These data are basic evidence of the clinical translation of nano-based transdermal systems, which highlights their ability to improve the therapeutic effectiveness of muscle relaxants ⁶.

FIG. 5: NANO-BASED TRANSDERMAL PATCH VS ORAL DRUG DELIVERY

Clinical Trials and Observational Studies in Humans: There are only a few studies on muscle relaxant patches, but the results that exist look quite encouraging. Medicines such as tizanidine and some others have been found to relax the muscles properly and cause fewer effects on the brain and nerves when compared to tablets. People also find using patches easier and more comfortable because they give fewer side effects to the whole body. For some problems like pelvic muscle pain, oral or vaginal relaxants can also work well when used along with other kinds of treatments ¹.

Older people, who often have to take many medicines and may have some memory issues, can benefit the most from these patches. The geriatric population, who are frequently facing the risks of polypharmacy and cognitive impairment, could gain the most out of transdermal therapies which offer the safety of lowering medication exposure without causing impairments in the therapeutic effect ³.

Transdermal Delivery of Other Muscle Relaxants that are related: In addition to tizanidine, off-label localized chronic pain control has been done using compounded topical creams with baclofen and cyclobenzaprine. Even though clinical support of these preparations is mostly anecdotal or narrow, they are useful supplements in multimodal analgesia especially where systemic medications cause unwanted side effects ¹⁷.

There is early indication of anti-inflammatory and muscle-relaxant effects of CBD, which could reduce the symptoms, but there is high heterogeneity in study designs and preparations, which makes it impossible to conclude on the efficacy ¹⁸.

These overlapping areas of investigations highlight the increased interest and theoretical possibilities of transdermal delivery of muscle relaxants and analgesics despite the need to conduct more specific efficacy trials ¹⁹.

Pharmacokinetics and Pharmacodynamics of Transdermal Muscle Relaxants:

Absorption, Distribution, Metabolism, and Elimination (ADME) Profiles: The use of transdermal administration changes the pharmacokinetic profile of muscle relaxants because it avoids the effects of gastrointestinal degradation and first-pass hepatic metabolism. This method provides a greater steady plasma levels, increases drug activity and improves the overall bioavailability of drugs like tizanidine ⁷. The barrier properties of the skin significantly affect transdermal absorption; the thickness of stratum corneum and skin hydration are some of the variables that alter the rate of drug permeation. The purpose of formulation technologies is to reduce these obstacles by improving the effectiveness of penetration but also providing regulated release kinetics ²⁰. Clinical research data show that transdermal delivery offers better availability of drugs and supports high levels of drugs over longer durations of time. The pharmacokinetic profile of this leads to less common dosing and better symptom control in patients with chronic musculoskeletal disorders ²¹.

Safety, Side Effects, and Tolerability of Drugs: Topical delivery of drugs through transdermal patches significantly reduces systemic side effects of sedation, mental retardation, and gastrointestinal discomfort that are usually related to oral systemic muscle relaxants (SMRs). Lower levels of the attenuated peak plasma minimize the chances of poisoning and toxicity ¹. The comparative study between oral baclofen and diazepam and transdermal agents reveals a reduced rate of unwanted CNS phenomena and dependence with transdermal tizanidine ²². However, continuous monitoring is still necessary, especially in rare adverse events and drug drug interactions due to polypharmacy, which is a common practice in clinical practice ²³.

The Effect of Genetic Polymorphisms on Drug Effectiveness: Differences in individuals responding to transdermal muscle relaxants are usually a manifestation of genetic polymorphisms that determine metabolic enzymes, transporters and sensitivity of receptors. The differences in cytochrome P450 enzymes, especially, CYP2C19, alter the pharmacokinetics of these agents and as such, the plasma concentrations and therapeutic actions. Variations in genes which influence the receptor structure may also change the drug binding affinity and physiological response which makes optimization of the dose harder. These pharmacogenetic issues call upon the need of a customized medicine treatment that relates pharmacogenomic profiling to customize transdermal treatment in order to maximize effectiveness and reduce the adverse events ⁹.

Comparison of Transdermal Formulations of SMRs and Other Analgesics:

Comparison of Efficacy and Patient Outcomes with Those of Oral and Injectable Forms: Transdermal muscle relaxants have several advantages as compared to the traditional ones through clinical studies that compare them to oral and injectable forms of muscle relaxants. Transdermal patches have a slow onset of action and have more sustained and consistent plasma drug concentrations, which encourage sustained muscle relaxation and analgesia. Patients exhibit an increased adherence rate because of the less frequency of dosing and the ease of patching¹. Furthermore, transdermal delivery has a better safety profile, lower sedation and cognitive disturbance, which enhances the functional outcome and quality of life of people with chronic musculoskeletal disorders ²⁰. Transdermal buprenorphine and fentanyl have shown effectiveness in some situations (e.g. postoperative pain management after major abdominal surgery), implying that it may be useful in other areas of muscle relaxation ²⁴.

FIG. 6: DRUG CONCENTRATION-TIME PROFILES FOR DIFFERENT ROUTES OF ADMINISTRATION

Combination Patches and Multimodal Therapy: Since, musculoskeletal pain and spasms are multifactorial, combination patches with SMRs and NSAIDs or any other analgesic have been created. Such formulations include baclofen, cyclobenzaprine, lidocaine, ketamine, and other agents in compounded creams and are aimed at different pain pathways simultaneously ¹⁷.

This type of multimodal topical therapy is capable of reducing the amount of systemic medication needed and the side effects involved and providing analgesic effects simultaneously. However, there are still challenges in terms of accuracy of dosing, stability of formulations, and regulatory control of compounded preparations ²⁵.

New Carriers and Where They Might Go: There are emerging nanocarriers, such as niosomes, liposomes and aspasomes, which have significant potential in improving muscle relaxant delivery through the transdermal route. These vesicular systems enhance drug stability, cutaneous permeability and regulated release and may result in better curative effects ⁵. The development and optimization of technology in the field of transdermal are still advancing, e.g. hybrid approaches, which involve a combination of chemical and physical permeation enhancers ¹¹. These formulations are, however, difficult to scale to commercial manufacture and regulatory approval and so, further research and standardization is necessary ¹⁴.

Technical and Manufacturing Considerations for Transdermal Muscle Relaxant Patches:

Materials and Patch Design Specification: The choice of polymer, development of adhesive, and addition of plasticizers are important in the creation of effective transdermal patches. Ethyl cellulose and Eudragit are polymers that form the structural frame work that determines the release kinetics of drugs ¹³. Plasticizers enhance the flexibility and skin conformity; the size of the patches should be optimized to a compromise between drug loading capacity and comfort to the patient. To ensure that the drug is effective across the shelf life of the product, stability tests are necessary to ensure that the drug remains effective even under different environmental conditions like humidity and temperature ¹⁴.

FIG. 7: STRUCTURE OF A TRANSDERMAL DRUG DELIVERY PATCH

Testing for Quality Control and Release Kinetics: Strong quality control involves in-vitro release tests, which are done in Franz diffusion cells to test transdermal permeation, and bring about stable drug release curves ¹². Physical characterization techniques measure weight consistency, folding strength to determine mechanical integrity and drug content consistency to ensure that the dose is consistent ¹³. Fourier-transform infrared spectroscopy (FTIR) is an analytical technique that establishes that the active ingredient and excipients are compatible. The evaluation of the thermal behavior and surface architecture give insights into formulation stability and performance through different scanning calorimetry (DSC) and surface electron microscopy (SEM) ²⁶.

Instructions for Packaging, Storing, and Using by Patients: Moisture and oxidation Repellent materials in protective packaging will lengthen patch stability. Guidelines on the choice of application sites, the duration of use and the time of changes can reduce cases of skin irritation and maintain treatment efficacy ¹. Vulnerable groups such as the elderly and the ones who are sensitive to the skin deserve special precautions, which will increase comfort and compliance ²⁶.

Safety, Tolerability, and Adverse Effects of Transdermal Muscle Relaxants:

Local Skin Reactions and Potential for Irritation: Adverse responses of local skin to transdermal patches include skin conditions like dermatitis, erythema, pruritus and sometimes blistering, which depend on the properties of the formulation as well as on skin sensitivity of an individual ⁷. The lack of adhesion can cause premature detachment and the experience of pain during removal can adversely affect patient compliance ¹⁴. They are addressed by formulation changes, including the use of skin-soothing agents and increased adhesive strength to minimize these problems and the overall patient experience ²⁷.

Side Effects and Drug Interactions in the Whole Body: The use of transdermal administration is linked with a lower rate of systemic adverse effects compared to oral dosing; however, when used concomitantly with numerous pharmacotherapies, a common situation in geriatric patients, it requires caution¹. Possible drug interactions, especially with the drugs that are metabolised by the cytochrome P 450 isoenzymes, can impair the effect and safety of therapy ²².

Continued observation of tolerance progress and the risk of dependence is a requirement; however, skeletal muscle relaxants like tizanidine have a favourable safety profile in this sense as a rule ²³.

Regulatory and Post-Marketing Surveillance: Transdermal systems have to undergo stringent preclinical and clinical testing by regulatory bodies to determine their safety, stability and effectiveness. The post-marketing surveillance is crucial in identifying the occurrence of rare adverse events and educating guideline development. Practical evidence gathering is requisite to optimize the selection criteria in patients and customize treatment plans ²⁵.

Research Deficiencies, Constraints, and Prospective Directions:

Existing Knowledge Deficiencies in Clinical Evidence: Although there is some initial evidence to support the efficacy and safety of transdermal skeletal muscle relaxants (SMRs), the lack of big, randomized controlled trials in addition to the dearth of long-term safety data and the difference in methodology hamper the development of clear clinical guidelines ¹. Existing transdermal SMRs have not been directly compared to each other thus making it difficult to determine which ones are better. These gaps need to be addressed so as to increase clinical utility ¹⁷.

Technological Problems in the Development of Drug Delivery: Limits on dermal permeability, molecular size, and inter-patient variability still limit the use of transdermal delivery to a range of SMR drug candidates. The challenge in manufacturing such as the ability to obtain consistency in formulation and scaled manufacturing, requires solutions that are innovative ⁵. A more mechanistic understanding of transdermal SMR pharmacodynamics will enable the development of individualized treatment plans that combine patient-specific variables of variable ¹¹.

New Trends and Ideas: Individualized medicine based on pharmacogenomic switching attempts to streamline dosing and therapeutic results. Modern studies are concerned with hybrid methods of delivery where chemical permeation enhancers are used in combination with physical methods of delivery including iontophoresis ⁷. Moreover, monitoring adherence and dose-optimisation through digital health platforms is indicative of a future of promising muscle relaxant therapies that are transdermal, which is a promising trend and direction in health care delivery and treatment ¹⁹.

CONCLUSION: They alleviate first-pass metabolism, inter-individual variability, and systemic drug effects. However, there remain technical and clinical barricades such as poor skin permeability, formulation instability and lack of solid clinical evidence. Continuous innovation and research are mandatory. Clinicians are advised to think about using transdermal SMR therapy and especially geriatric patients or those on polypharmacy regimen whereby the reduction of systemic exposure is the most important consideration. This modality should be incorporated into the overall pain and spasm management programs, paying close attention to the details of the formulation and the peculiarities of a particular patient. Transdermal technologies will yield optimal therapeutic decision-making. The priorities of the future should include large scale randomised controlled trials, exploration of new nanocarrier systems, and integration of personalised medicine systems. The regulatory channels should be changed to promote innovation, and high standards of safety should be observed. Finally, it is possible that transdermal delivery systems can significantly improve the quality of life of patients with musculoskeletal conditions through providing a more effective muscle-relaxation therapy.

ACKNOWLEDGEMENTS: Nil

CONFLICTS OF INTEREST: Nil

REFERENCES:

1. Z. Lingling Zhu Yanhong Wang, “Tizanidine: Advances in pharmacology & amp; therapeutics and drug formulations,” Dove Medical Press 2024.
2. Chou R, Peterson K & Helfand M: Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. Journal of Pain and Symptom Management 2004; 28(2): 140-175.
3. C. V. Flatow J. Uy-Kroh: “Skeletal muscle relaxants for the treatment of myofascial pelvic pain and high tone pelvic floor disorders,” Current Opinion in Obstetrics and Gynaecology 2023.
4. P. Sadab Sarad Sahu: “A comprehensive review: Transdermal drug delivery system: A tool for novel drug delivery system.” None 2022.
5. H. Ahlam Zaid Alkilani Jehad Nasereddin: “Beneath the skin: A review of current trends and future prospects of transdermal drug delivery systems.” Multidisciplinary Digital Publishing Institute 2022.
6. R. S. S. I. Hadebe P. Ngubane: “Transdermal delivery of insulin by amidated pectin hydrogel matrix patch in streptozotocin-induced diabetic rats: Effects on some selected metabolic parameters.” PLoS ONE 2014.
7. Khalil RM, Abdelbary A, Kocova El‐Arini S, Basha M and El-Hashemy HA: Development of tizanidine loaded aspasomes as transdermal delivery system: ex-vivo and in-vivo J Liposome Res 2021; 31(2): 171-182. PMID: 31646921.
8. Z. Stefan Quasthoff Claudia Mckel: “Tolperisone: A typical representative of a class of centrally acting muscle relaxants with less sedative side effects.” Wiley 2008.
9. E. Yan Sun Hongyu Zhu: “Mechanisms and implications in gene polymorphism mediated diverse reponses to sedatives, analgesics and muscle relaxants.” Korean Journal of Anesthesiology 2022.
10. D. Hale Karagzel Sezen Sivrikaya zak: “Investigation of permeability of thiocolchicoside through transdermal drug delivery system using franz diffusion cell.” Sakarya University 2024.
11. T. Rita Muzzalupo: “Niosomal drug delivery for transdermal targeting: Recent advances.” Dove Medical Press 2015.
12. H. C. Omar Shafi Michelle Swer: “SurfactantModified ProgesteroneLoaded PVP/cellulose fibres for future drug delivery applications in menopause.” None 2025.
13. V. Bhambar: “Formulation and evaluation of transdermal patches of drotaverine hydrochloride using mercury substrate method.” Journal of Medical Pharmaceutical and Allied Sciences 2021.
14. E. A. Ibrahim Alissa Anroop B Nair: “Design, development, and evaluation of treprostinil embedded adhesive transdermal patch.” Pharmaceutics 2023.
15. B. M. Mohammad Al-Khalili Victor M: Meidan, “Iontophoretic transdermal delivery of buspirone hydrochloride in hairless mouse skin.” American Association of Pharmaceutical Scientists 2003.
16. I. Kazumasa Kubota Tomoyuki Miyamoto: “Alternating current iontophoresis for control of postoperative pain,” Allen Press 2018.
17. B. Robert E. Brutcher Connie Kurihara: “Compounded topical pain creams to treat localized chronic pain.” Annals of Internal Medicine 2019.
18. W. Aleksandra Nitecka-Buchta Anna Nowak-Wachol: “Myorelaxant effect of transdermal cannabidiol application in patients with TMD: A randomized, double-blind trial.” Multidisciplinary Digital Publishing Institute 2019.
19. N.-B. Karolina Walczyska-Drago Jakub Fiegler-Rudol: “Cannabidiol for orofacial and upper-quarter pain: A systematic evaluation of therapeutic potential.” Journal of Clinical Medicine 2025.
20. E. M. Allan Gordon Saifudin Rashiq: “Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain.” Hindawi Publishing Corporation 2010.
21. E. M. Hue Jung Park: “Pharmacologic management of chronic pain.” The Korean Pain Society 2010.
22. V. Milica Prostran Katarina Savi Vujovi: “Pharmacotherapy of pain in the older population: The place of opioids.” Frontiers Media 2016.
23. Benyamin, “Opioid complications and side effects.” American Society of Interventional Pain Physicians 2008.
24. G. Zia Arshad Ravi Prakash: “Comparison between transdermal buprenorphine and transdermal fentanyl for postoperative pain relief after major abdominal surgeries.” JCDR Research and Publications Private Limited 2015.
25. H. Shraddha Mahabole Balakrishna Tiwari: “Formulation and evaluation combination of anti-inflammation and skeletal muscle relaxant gel.” International Journal for Multidisciplinary Research 2025.
26. M. A. Mona G. Arafa: “DOE optimization of nano-based carrier of pregabalin as hydrogel: New therapeutic & chemometric approaches for controlled drug delivery systems.” Nature Portfolio 2017.
27. S. W. S. P. Cohen Thomas M. Larkin: “Multicenter, randomized, placebo-controlled crossover trial evaluating topical lidocaine for mechanical cervical pain.” Anesthesiology 2023.
28. Karthikeyan E: Advancements in transdermal drug delivery systems. Science Direct 2024.
29. Su Zhang VR, Niu F and Lee EA: Safety of baclofen versus tizanidine for older adults with musculoskeletal pain. J Am Geriatr Soc 2023; 71: 2579–2584. doi:10.1111/jgs.18349
30. Kamran M: Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In-vitro characterization and in-vivo pharmacokinetic assessment. Int J Pharm 2016; 505: 147–158.
31. Zhu K, Devine A, Dick IM and Prince RL: Association of back pain frequency with mortality, coronary heart events, mobility, and quality of life in elderly women Spine 2007; 32: 2012-2018.
32. Alkilani AZ, McCrudden MT and Donnelly RF: Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics 2015; 7(4): 438–470.
33. Florence AT and Baillie AJ: Nonionic surfactant vesicles – alternatives to liposomes. In: Prescott LF, Nimmo WS, editors. Novel Drug Delivery and its Therapeutic Application. New York, NY, USA: John Wiley and Sons Ltd 1989.
34. Yang J and Pal R: Polymers (Basel) 2020; 12: 2302.
35. Katta Manogna and Shilpa TN: Development of Medicated Topical Patches in Transdermal drug delivery system. Research J Pharm Tech 2018; 11(1): 397-404.
36. Alkilani AZ and McCrudden MT: Donnelly, R.F. Transdermal Drug Delivery: Innovative Pharmaceutical Developments Based on Disruption of the Barrier Properties of the stratum corneum. Pharmaceutics 2015; 7: 438–470.
37. Banga AK: Electrically Assisted Transdermal and Topical Drug Delivery. London, England: Taylor and Francis 1998.
38. Eccleston C, Cooper TE, Fisher E, Anderson B and Wilkinson NM: Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. Cochrane Database Syst Rev 2017; 8: 12537.
39. Koh JC, Lee J, Kim SY, Choi S and Han DW: Postoperative pain and intravenous patient-controlled analgesia-related adverse effects in young and elderly patients: a retrospective analysis of 10,575 patients. Medicine (Baltimore) 2015; 94: 2008. doi: 10.1097/MD.0000000000002008.
40. Pinto RZ: Drugs for relief of pain in patients with sciatica: systematic review and meta-analysis. Br Med J (Clin Res Ed) 2012; 344: 497.
    

    ---

    How to cite this article:

    Ballarpure N, Yadav N and Dhawande A: A review article on transedermal patches used for muscle relaxation. Int J Pharm Sci & Res 2026; 17(5): 1396-05. doi: 10.13040/IJPSR.0975-8232.17(5).1396-05.

    ---

    All © 2026 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.